NCT05507931Completed
Broccoli Sprouts for Mild Ulcerative Colitis
A Pilot Feasibility Study to Develop a Broccoli Sprouts-enriched Diet in the Management of Ulcerative Colitis
Source: ClinicalTrials.gov · Last updated 23 Jan 2026
Brief summary (registry, in English)
The goal of this study is to determine the number of servings of broccoli sprouts sufficient to (1) increase sulforaphane levels in the stool and blood and (2) reduce inflammatory markers in patients with mild ulcerative colitis. This is a pilot feasibility study to prepare for a larger randomized controlled trial.
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 23 (actual)
- First submitted
- 17 Aug 2022
- Start date
- 23 May 2023
- Primary completion date
- 9 Jan 2026
- Lead sponsor
- University of Michigan
- Diseases
- Ulcerative colitis
- NCT number
- NCT05507931
What you commit to
- Study type: Interventional
- Participants enrolled: 23
- From 23 May 2023 to the primary completion date, 9 Jan 2026
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Taking Non-steroidal anti-inflammatory drugs (NSAIDs)
- Antibiotics in the previous 2 weeks
Other illness
- Newly diagnosed (within past month), or uncontrolled diabetes or cardiovascular disease
- Consumption of more than 5 ½ cups of servings/day of fruits and vegetables as assessed by the National Cancer Institute (NCI) Diet History Questionaire III online Food Questionnaire.
- A known allergy or sensitivity to cruciferous vegetables like arugula, bok choy, broccoli, cabbage, cauliflower, or collard greens
Other
- Following a medically-prescribed diet, on Total parenteral nutrition (TPN), or tube feeds
Who the study is looking for
- Documented endoscopic diagnosis of ulcerative colitis
- Currently being treated with a stable dose of 5-ASAs, steroids, or any other medication approved for ulcerative colitis
- If on 5-ASA, no dose changes within 2 weeks before the Day 0 visit
- If on steroids, prednisone dose not more than 20 mg daily and entocort not more than 9 mg daily, with no dose changes within 2 weeks before the Day 0 visit
- All other medications require a stable dose for at least 8 weeks prior to enrollment.
- No dose changes to any IBD medication anticipated for the duration of the study
- Body Mass Index (BMI) values 18.5-40 kg/m2
- Not on total parenteral nutrition (TPN) or receiving tube feeds.
- Ability to understand the study procedures, benefits and risks, and sign a written informed consent document.
- Able to fill out questionnaires regarding dietary intakes, bowel symptoms, and study experience
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Michigan Coordinator of this site? Confirm its status | Ann Arbor | United States | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.